- Home
- Products
Tibsovo (Ivosidenib)
Tibsovo (Ivosidenib)
- Medicine Name: Tibsovo
- Generic Name: Ivosidenib
- Dosage Form & Strength: Tablets – 250 mg
- Manufactured By: Servier Pharmaceuticals
Tibsovo (Ivosidenib) is a targeted oral therapy approved for adult patients with confirmed isocitrate dehydrogenase-1 (IDH1) mutation. It offers new treatment options for patients who have limited alternatives for the following conditions:
- Acute Myeloid Leukemia (AML):
- Newly diagnosed AML in adults aged ≥75 or unfit for intensive chemotherapy, used alone or in combination with azacitidine
- Relapsed or refractory AML
- Newly diagnosed AML in adults aged ≥75 or unfit for intensive chemotherapy, used alone or in combination with azacitidine
- Myelodysplastic Syndromes (MDS):
- For patients with relapsed or treatment-resistant MDS
- For patients with relapsed or treatment-resistant MDS
- Metastatic Cholangiocarcinoma (Bile Duct Cancer):
- In previously treated adults with IDH1-mutated bile duct cancer
Mechanism of Action:
Ivosidenib works by inhibiting mutant IDH1 enzyme activity, reducing abnormal 2-HG (2-hydroxyglutarate) levels, a key driver in tumor progression. This mechanism leads to the restoration of normal cell differentiation and reduction in cancer cell proliferation.
Note: Treatment eligibility is determined by IDH1 mutation testing.
Differentiation Syndrome (AML): May occur during treatment and can be life-threatening. If suspected, begin corticosteroids (e.g., dexamethasone 10 mg IV every 12 hours) and monitor closely. Discontinue Tibsovo if symptoms persist beyond 48 hours despite treatment.
QTc Prolongation: QT interval prolongation and arrhythmias may develop. Monitor ECG and electrolytes regularly. Discontinue permanently in patients experiencing life-threatening arrhythmias.
Pregnancy & Breastfeeding: Tibsovo may cause fetal harm. Avoid use during pregnancy. Women of reproductive potential should use contraception during and for 1 month post-treatment. Do not breastfeed during treatment and for at least 1 month after the last dose.
Storage: Store at 20°C to 25°C. Excursions permitted between 15°C to 30°C. Protect from excess heat and moisture.
Documents Required to Import Tibsovo into India:
- Prescription from a registered medical practitioner
- Diagnostic test reports confirming IDH1 mutation
- Government-issued ID proof of the patient
Availability in India:
Tibsovo is available for import into India under the Named Patient Program for personal use.
Global Rare Meds Offers:
- Sourcing from licensed suppliers in the USA, Europe, Canada, and Australia
- Transparent pricing and import compliance support
- Supply to major Indian cities such as Delhi, Mumbai, Bengaluru, Pune, Kolkata, Chennai, Hyderabad, Ahmedabad, and more
📧 info@globalraremeds.com
📞 +91-99675 15602 (Call/WhatsApp)
Global Rare Meds ensures timely sourcing of Tibsovo (Ivosidenib) from trusted international suppliers. All orders are processed through our licensed fulfillment center in Ambernath, Thane District, India.
We provide:
- Cold-chain compliant logistics (if applicable)
- Pharmacist-verified dispensing
- Regulatory-compliant delivery directly to patient/hospital
Q: What is the generic name of Tibsovo®?
A: Ivosidenib
Q: Who manufactures Tibsovo®?
A: Servier Pharmaceuticals
Q: Is Tibsovo® FDA-approved?
A: Yes, Tibsovo was approved by the U.S. FDA on July 20, 2018.
Q: What dosage form is available?
A: Tibsovo is supplied as 250 mg oral tablets.
Q: What are the most common side effects in AML patients?
A: Diarrhea, fatigue, nausea, elevated liver enzymes, joint pain, shortness of breath, rash, and differentiation syndrome.
Q: What are the most common side effects in cholangiocarcinoma?
A: Fatigue, nausea, abdominal pain, diarrhea, anemia, vomiting, cough, and ascites.
Q: What are the storage conditions?
A: Store at room temperature between 20°C and 25°C. Protect from moisture. Do not store outside original packaging.
Q: How much does Tibsovo® cost in India?
A: The cost varies based on source and destination. For current pricing, contact info@globalraremeds.com or +91-99675 15602.
Q: Can Tibsovo® be purchased online in India legally?
A: Yes. Global Rare Meds can help patients legally procure Tibsovo with a valid prescription through authorized channels.
Q: Is Tibsovo chemotherapy?
A: No. Tibsovo is not a traditional chemotherapy drug. It is a targeted therapy for IDH1-mutated cancers.
Q: Is Tibsovo available outside India?
A: Yes, we can facilitate legal supply to countries across South Asia, including Maldives, Bangladesh, Nepal, Bhutan, Sri Lanka, Pakistan, and Afghanistan.
Q: What is the diagnostic requirement before using Tibsovo?
A: IDH1 mutation must be confirmed using an approved diagnostic test such as the Abbott RealTime IDH1 Assay.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
